Mylan Inc., the generic-drug maker with an exclusive agreement to sell a copy of GlaxoSmithKline Plc’s Paxil CR, lost its bid for a preliminary court order blocking Apotex Inc. from also selling the antidepressant medicine.
“We can confirm that Mylan’s application for a preliminary injunction was denied, and we are pleased with the result,” said Sarah Alspach, a spokeswoman for GlaxoSmithKline.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
